Prefilled Syringes Market

FDA Approvals in Full Swing, Prefilled syringes Market Gets a Boost
Prefilled syringes industry has become one of the fastest growing industries in the medical
devices sector. Medical professionals have rolled up their sleeves for the optimum utilization of
prefilled syringes due to their advantages over traditional vial-based syringes, improved safety
& efficiency, and enhanced convenience. The continual advancements in syringe technologies
and material have enabled better and safer delivery of drugs, vaccines, therapeutic proteins,
and blood stimulants. According to the leading research market firm Allied Market Research,
the global prefilled syringes market garnered $3,567 million in 2016, and is projecte4d to reach
$7,212 million by 2023, registering a CAGR of 10.5% from 2017 to 2023.
The enormous market potential has been identified by many manufacturing companies.
German healthcare device producer Gerresheimer started establishing the fourth
manufacturing line for prefilled syringes to its plant situated in Bünde. The drug contamination
risk reducing syringes have gained popularity across the world. The U.S. Food & Drug
Administration (FDA), the leading authority that approvals new drugs, products, and
technologies in the medical sector in the U.S. has recently approved many prefilled syringes for
various conditions. Following are some of the approved products for different health
conditions:
Adamis Epinephrine Prefilled Syringe:
Adamis Pharmaceuticals Corporation received an FDA approval for its Epinephrine prefilled
syringe for treatment of allergic reactions including anaphylaxis. It is a 0.3 mg prefilled single
dose syringe (PFS). It also received a trade name of Symjepi. This offers two single dose
syringes of epinephrine(adrenaline), which is a drug of choice for instant administration in the

acute anaphylactic reactions to insect bites or stings. Moreover, this dose can be administrated
in the allergic reaction to foods, drugs, and other allergens. Idiopathic or exercise-induced
anaphylaxis can also be treated with this drug.
Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We are very excited by this approval,
and at the same time, are already preparing to submit our second NDA to the FDA. This second
submission is for the junior version of Symjepi. We are committed to helping patients by
providing them with additional therapeutic choices.”
He also stated that Symjepi would become the favorite option for patients and medical
professionals owing to small size, low cost, and user-friendly design. The company has been
seeking commercialization options and discussions with potential partners have been
conducted to widen patient access.
Genentech’s Lucentis 0.3 mg:
Genentech revealed that the FDA has approved Lucentis 0.3 mg prefilled syringe for treatment
of diabetic retinopathy condition with or without diabetic macular edema(DME). The company
stated that this syringe has been made available from the second quarter of 2018. This syringe
is made up of borosilicate glass and a single-use sterile & sealed tray is used to package. It
eliminates a lot of preparation work of medical professionals and enables them to administrate
Lucentis instantly. Physicians do not have to pull the medicine from vial, disinfect it, or attach
the needle with the help of administration method. The FDA has also approved Lucentis 0.5 mg
prefilled syringe for macular edema after retinal vein occlusion, wet age-related macular
degeneration, and myopic choroidal neovascularization.
“With the PFS, physicians will have a new option for administering Lucentis to the hundreds of
thousands of people in the U.S. diagnosed with either wet AMD or macular edema after RVO,”
said Sandra Horning, MD, chief medical officer and head of global product development at
Genentech. “Today’s approval of the Lucentis 0.3 mg prefilled syringe reinforces our
commitment to advancing therapy for those impacted by this vision-threatening disease.”
The FDA has also approved Lucentis 0.5 mg prefilled syringe for macular edema after retinal
vein occlusion, wet age-related macular degeneration, and myopic choroidal
neovascularization. The press release on approval of Lucentis 0.3 mg syringe also stated that
physicians and medical professionals can take off the syringe cap, connect an injection needle
to syringe, and adjust the dose prior to administration. The 0.3 mg syringe needs to be prefilled
with an anti-VEGF agent. This agent has been approved the FDA for treatment of diabetic
retinopathy and DME.
Philip Storey, MD, MPH at the Wills Eye Conference and colleagues found that anti-VEGF
injection administrated via prefilled syringe lowers the risk of endophthalmitis as compared to
administration through the conventional method of injection. Storey said, “The odds of

endophthalmitis infection was 2.5 times higher with the conventional medication than with the
prefilled medication.”
After careful consideration and pool of data, Storey and team discovered that an incidence of
endophthalmitis when injection was given through prefilled syringes was one in 9,050, while it
was one in 3,413 through the conventional method of injection. This showed that prefilled
syringes offer a safer way to administrate drugs in patients. The industry has been riding on a
trend of innovation to address concerns regarding safety of conventional way of injection. More
innovative products will be launched and approved by the FDA in coming years.
Read more at: https://www.alliedmarketresearch.com/prefilled-syringes-market